VEGFA and cancer: In addition, some cancers may acquire resistance to anti-PD1/PDL1 therapies over time, resulting in T-cell exhaustion by virtue of different mechanisms, including enhancement of PD1 or VEGF expression, with the latter manifesting as suppression of the cytotoxicity of immune cells.